Pharmaceutical

Grifols gears up for FDA approval of fibrinogen replacement therapy

Grifols’ Phase III AdFIrst trial met its primary endpoint and the company plans to file for approval in Q4 2024.

Feb 14, 2024 - 18:00
Grifols gears up for FDA approval of fibrinogen replacement therapy
Grifols’ Phase III AdFIrst trial met its primary endpoint and the company plans to file for approval in Q4 2024.
Read the original article

Tags:

Previous Article

BMS signs $674m GenAI drug discovery deal with VantAI

Next Article

Sudo secures additional funds to advance TYK2 inhibitors to clinic

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: I learned the hard way that U.S. airlines are not currently required to have EpiPens

Opinion: I learned the hard way that U.S. airlines are ...

Aug 1, 2023

Rare-disease doctors support expanded newborn genomic screening, survey finds

Rare-disease doctors support expanded newborn genomic s...

May 9, 2023

STAT+: Up and down the ladder: The latest comings and goings

STAT+: Up and down the ladder: The latest comings and g...

Mar 19, 2023